EyeCRO specializes in preclinical ophthalmic studies to examine the efficacy of novel test agents and therapeutic modalities. Our models are well established and optimized to facilitate generation of reproducible datasets with meaningful endpoints.
With over two decades of experience in vision research, our expert scientists can help you select the right model and experimental design to achieve your research and development goals. We also offer Toxicology/PK studies, and eyedrop formulations in MiDROPS™.
The Global Leader in Preclinical Ophthalmic Research
Microemulsion Drug Ocular Penetration System MiDROPS™
MiDROPS™ was developed to allow for eyedrop formulation of small molecules that are lipophilic. This technology represents a fundamentally new approach for ophthalmic drug delivery using microemulsions which are thermodynamically stable. These self-assembling vehicles can formulate high concentrations of drugs and deliver them in abundant quantities to both the anterior segment and posterior segment. Our broad patents are issued in the US and Worldwide and protect millions of different formulations covered in our library.
Click here to learn more about this innovative platform technology
News & Events
EyeCRO scientists contribute to paper published in Biology
Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization Click here to read more
EyeCRO scientists contribute to paper published in BiologyRead More
EyeCRO scientists contribute to study published in Experimental Eye Research
Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model. Click here to read more
EyeCRO scientists contribute to study published in Experimental Eye ResearchRead More
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids
Inmed Pharmaceuticals Inc. (NASD: INM) has secured a worldwide license to formulate any cannabinoid molecule using MiDROPS® for ophthalmic instillation. Click here to read the full press release.
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic CannabinoidsRead More
EyeCRO scientists contribute to study published in Nature
“Researchers have discovered a technique for directly reprogramming skin cells into light-sensing rod photoreceptors used for vision. The lab-made rods enabled blind mice to detect light after the cells were transplanted into the animals’ eyes. The…
EyeCRO scientists contribute to study published in NatureRead More
Is Treat-and-Extend Truly Effective for Diabetic Macular Edema?
“Anti-vascular endothelial growth factor (anti-VEGF) medications have a proven track record in treating diabetic macular edema (DME). However, researchers continue to investigate whether these medications can be made more efficient and cost-effective.” “Both the RETAIN and REACT studies showed that…
Is Treat-and-Extend Truly Effective for Diabetic Macular Edema?Read More
New Age-Related Macular Degeneration Common in Untreated Fellow Eyes
“NEW YORK (Reuters Health) – New age-related macular degeneration (AMD) develops in about a quarter of fellow eyes to those treated for neovascular AMD with intravitreal anti-VEGF agents, according to a post hoc analysis of the…
New Age-Related Macular Degeneration Common in Untreated Fellow EyesRead More
EyeCRO on Twitter
EyeCRO – Headquarters
Oklahoma City, OK 73105
EyeCRO – Ann Arbor
Ann Arbor, MI 48104